Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
29.8M
-
Shares change
-
+543K
-
Total reported value, excl. options
-
$446M
-
Value change
-
+$8.59M
-
Put/Call ratio
-
0.49
-
Number of buys
-
70
-
Number of sells
-
-41
-
Price
-
$14.98
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2022
141 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q4 2022.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.8M shares
.
Largest 10 shareholders include BlackRock Inc. (3.58M shares), VANGUARD GROUP INC (3.23M shares), BAKER BROS. ADVISORS LP (2.8M shares), HHLR ADVISORS, LTD. (2.62M shares), Rubric Capital Management LP (1.57M shares), STATE STREET CORP (1.49M shares), PICTET ASSET MANAGEMENT SA (1.23M shares), GOLDMAN SACHS GROUP INC (1.02M shares), MILLENNIUM MANAGEMENT LLC (771K shares), and ArrowMark Colorado Holdings LLC (717K shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.